NLRP3 and type 2 diabetes mellitus: Analysis of macrophages from people with type 2 diabetes treated with empagliflozin or sulfonylurea demonstrated that the SGLT2 inhibitor was more efficient in the attenuation of NLRP3 activation in macrophages as compared to sulfonylurea, and more efficiently suppressed IL-1β secretion [31].